Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 6:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Colonoscopy
Interventions: Bowel Prep; Drug
Lead sponsor: Braintree Laboratories; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 34
States / cities: Tucson, Arizona • Little Rock, Arkansas • North Little Rock, Arkansas + 29 more

Conditions: Diabetes, Autoimmune
Interventions: DiaPep277; Drug
Lead sponsor: DeveloGen Israel, Ltd.; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 7
States / cities: Birmingham, Alabama • Aurora, Colorado • Lexington, Kentucky + 4 more

Conditions: Non-cystic Fibrosis Bronchiectasis
Interventions: Benralizumab, Placebo to Benralizumab; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Birmingham, Alabama • Newport Beach, California • Northridge, California + 1 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: GSK5784283, Placebo, Standard of care; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Doral, Florida • Lake Charles, Louisiana • Humble, Texas + 2 more

Conditions: Psoriasis
Interventions: Mirikizumab, Placebo, Secukinumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 42
States / cities: Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 37 more

Conditions: Pain, Postoperative
Interventions: N1539, Placebo; Drug
Lead sponsor: Baudax Bio; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Florence, Alabama • Mobile, Alabama • Sheffield, Alabama + 3 more

Conditions: Prevention From Norovirus Infection
Interventions: Norovirus Bivalent Vaccine, Saline Comparator; Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: Atlanta, Georgia • Baltimore, Maryland • Rochester, New York + 2 more

Conditions: Asthma, Coronary Artery Disease, Pulmonary Disease, Chronic Obstructive
Interventions: Regadenoson, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 1,009 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 48
States / cities: Montgomery, Alabama • Anaheim, California • Encinitas, California + 43 more

Conditions: Asthma Acute
Interventions: Rademikibart in prefilled syringe, Matching placebo in prefilled syringe; Combination Product · Drug
Lead sponsor: Connect Biopharm LLC; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 21
States / cities: Palo Alto, California • Valencia, California • Wilmington, Delaware + 17 more

Conditions: Breast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
Interventions: Olaparib, Physician's choice chemotherapy; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 42
States / cities: San Diego, California • Santa Rosa, California • Whittier, California + 35 more

Conditions: COPD
Interventions: Targeted Lung Denervation (TLD), Optimal Medical Care; Device · Other
Lead sponsor: Nuvaira, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 17 more

Conditions: Inflammatory Bowel Disease
Interventions: Filgotinib, Placebo, Standard of Care; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 21 Years to 65 Years · Male only
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 10
States / cities: San Diego, California • Lakewood Rch, Florida • Miami, Florida + 7 more

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Placebo, Adalimumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 9
States / cities: Beverly Hills, California • Encino, California • Irvine, California + 6 more

Conditions: Alzheimer Disease
Interventions: sabirnetug, Placebo; Drug
Lead sponsor: Acumen Pharmaceuticals; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 44
States / cities: Carlsbad, California • Fullerton, California • Irvine, California + 40 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: BI 1015550, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 1,177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 56
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 45 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec, insulin glargine, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,006 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 66
States / cities: Alexander City, Alabama • Birmingham, Alabama • Goodyear, Arizona + 61 more

Conditions: Delayed Onset Muscle Soreness
Interventions: Loxoprofen Pain Patch, Placebo Patch, No Treatment; Drug
Lead sponsor: Lead Chemical Co., Ltd.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Parkinson Disease
Interventions: K0706, Placebo; Drug
Lead sponsor: Sun Pharma Advanced Research Company Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 5
States / cities: Long Beach, California • Panorama City, California • DeLand, Florida + 2 more

Conditions: Lambert Eaton Myasthenic Syndrome
Interventions: Amifampridine Phosphate, Placebo; Drug
Lead sponsor: Catalyst Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 6
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 3 more

Conditions: Ankle Arthrodesis or Arthroplasty, Hindfoot Fusion, Ankle Deformity, Ankle Disease, Hindfoot Arthrodesis, Hindfoot Pathologies
Interventions: MagnetOs, Autograft; Device · Other
Lead sponsor: Kuros Biosurgery AG; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Sacramento, California • Vail, Colorado • Columbus, Georgia + 4 more

Conditions: Underage Drinking, Cannabis Use, Drinking, Teen, Drinking, College, College Drinking, Teen Drinking
Interventions: e-PBI; Behavioral
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 19 Years
Enrollment: 1,980 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Asthma
Interventions: Omalizumab, Placebo, Fluticasone; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 56
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more

Conditions: Parkinson's Disease, Levodopa Induced Dyskinesias (LID)
Interventions: 240mg Amantadine HCl ER tablets, Placebo tablets, 320mg Amantadine HCl ER tablets; Drug
Lead sponsor: Adamas Pharmaceuticals, Inc.; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 26
States / cities: Tucson, Arizona • Fountain Valley, California • Irvine, California + 21 more

Conditions: Psoriatic Arthritis
Interventions: Izokibep, Placebo to izokibep; Drug
Lead sponsor: ACELYRIN Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 40
States / cities: Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 37 more

Search by objective public record fields.

Study 302: BLI4900 Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy

Safety, Tolerability, Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in Latent Autoimmune Diabetes in Adults (LADA)

Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis

A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)

A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

Evaluation of Preoperative N1539 in Total Knee Arthroplasty

Norovirus Bivalent-Vaccine Efficacy Study

A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease

Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

Evaluation of the Safety and Efficacy of TLD in Patients with COPD

Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease

Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically

A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes

Pilot Study Comparing the Efficacy and Safety of a New Pain Patch and Placebo in Delayed Onset Muscle Soreness (DOMS)

Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease

A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

A Prospective, Randomized, Single-blind, Controlled, Multi-center Study to Assess the Safety and Performance of MagnetOsTM Compared to Autogenous Bone Graft in Patients Undergoing Hindfoot or Ankle Fusions.

Project e-PBI+ - Parent Intervention to Reduce College Student Drinking and Cannabis Use

Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.

Psoriatic Arthritis Study of Izokibep